08:03 EDT Sage Therapeutics down 19% at $12.60 after announcing dalzanemdor Phase 2 data
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- SAGE Therapeutics’ Promising Parkinson’s Treatment Results
- Sage Therapeutics management to meet with Piper Sandler
- SAGE Therapeutics Board Member Announces Retirement
- Sage Therapeutics price target raised to $29 from $24 at JPMorgan
- JPMorgan biotech analysts to hold an analyst/industry conference call
